Premium
Acusphere Inc New (CE) (ACUS)
USOTC
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Acusphere, Inc. (ACUSD.PK) announced today the strategic decision to voluntarily withdraw its Marketing Authorization Application (MAA) submitted to the European Medicines Agency’s Committee...
Acusphere, Inc. (ACUSD.PK) today announced that William I. Ramage, D. Phil., has been appointed Chief Development Officer of the Company. Acusphere is focused on the development of Imagify™...
-- Co-founder Sherri Oberg to remain as Vice Chairman of the Board --
Acusphere, Inc. (ACUSD.PK) today announced that it has submitted the Marketing Authorisation Application (MAA) for its lead product candidate, Imagify™ (Perflubutane Polymer...
Acusphere Inc. (OTCBB: ACUS) announced today its plan to substantially reduce costs while it continues its discussions with the U.S. Food & Drug Administration (FDA) about the...
Acusphere Inc. (OTCBB: ACUS) announced today that it has submitted an amendment to its New Drug Application (NDA) for ImagifyTM (Perflubutane Polymer Microspheres) for...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 0 | 0 | CS |
| 26 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 100 | 1.0E-6 | CS |
| 52 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 455 | 1.0E-6 | CS |
| 156 | -9.0E-6 | -90 | 1.0E-5 | 1.0E-5 | 1.0E-6 | 2893 | 1.0E-6 | CS |
| 260 | -0.025999 | -99.9961538462 | 0.026 | 0.1779 | 1.0E-6 | 11483 | 0.03366264 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
